Single-use bioprocessing boom fuels vendor windfall

In early October 2026, IndexBox made the growth case explicit for a core single-use category, saying the wave/rocking bioreactor market entered the year with “broader demand fundamentals” and a “phase of sustained expansion, supported by the biopharmaceutical industry's structural shift toward flexible, single-use manufacturing.” That mattered because the report did not stop at near-term momentum: it projected the market would “expand at a compound annual growth rate of 8.2%, reaching a market index of 220 by 2035 (2025=100),” while also signaling that consumables tied to these systems would outgrow hardware.

A separate October 2026 analysis of Sartorius showed the same pattern surfacing in company outlooks as well as market research, with management expecting the “Bioprocess Solutions market to expand by 8-10% annually,” backed by “rising demand for biologic medicines” and a pipeline “increasingly weighted towards new modalities.” The significance for single-use was strategic as much as financial: the analysis argued that as adoption advances from development into commercial manufacturing, suppliers gain not only equipment demand but a larger recurring consumables base, reinforcing why late-2026 earnings commentary pointed to expansion across both technologies and materials.

The growth case is strongest where single-use directly changes how bioprocessing gets done: Grand View Research says these systems cut cleaning and sterilization demands, lower cross-contamination risk, shorten commissioning timelines, and reduce upfront capital versus stainless steel, which makes rapid deployment and frequent process changes far easier in development settings. That matters because biologics, cell and gene therapy programs, and CDMO work increasingly require flexible perfusion platforms, so the operational logic of single-use is not theoretical demand creation but a practical response to faster-turn process development and multiproduct manufacturing needs.

Adoption is also broad enough to reshape supplier economics and product strategy, not just individual workflows: “By product type: Single-use perfusion bioreactors segment held the highest market share of 70.2% in 2025,” according to Grand View Research, even though the model carries lower initial capital expenditure but higher consumable operating costs. That tradeoff helps explain why vendors are expanding integrated platforms and the attached consumables stream, as seen when, in September 2025, Distek expanded its BIOne Single-Use Bioreactor portfolio with perfusion-ready 2 L, 5 L, and 10 L systems intended to support process development, scale-up, and small-scale production.

By late October 2026, Thermo Fisher had turned the broader growth narrative into something visible on the income statement. AlphaStreet News summed it up in a headline that left little ambiguity: “Thermo Fisher Beats Forecast: $6.68 EPS, $12.14 B Revenue; CEO Marc Casper Hails Growth Strategy,” a result that directly confirmed the company’s growth strategy was delivering and gave investors a concrete read-through that demand tied to bioprocessing expansion was translating into earnings strength rather than remaining a thematic expectation.

That signal strengthened days later when BioSpace reported, “Thermo Fisher Posts $12.14B Q3, 15% EPS Jump, Unveils Orbitrap Isora, Raises Outlook,” pairing strong quarterly performance with a higher forecast and fresh investment messaging around instrumentation. The combination mattered because it suggested management was not treating the quarter as an isolated beat: raised guidance, alongside a new product launch, aligned with contemporaneous market reports projecting continued expansion and helped make late October and early November 2026 the moment the growth story became harder to dismiss.